Clinical trials: Reproductive Disorder
Ovarian Cancer, Breast Cancer
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
- Trial name
- NCT05258747
- Testing
- Olaparib tablets, 150 mg, Lynparza® (olaparib) tablets 150 mg
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Sandoz
Polycystic Ovary Syndrome
A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation
This is a Phase IV, prospective, observational, single arm, multicenter trial to identify the population at high risk of overstimulation associated with signs and symptoms of PCOS and examines the utility of 12.5 international…
- Trial name
- ARTIST (NCT02607293)
- Testing
- Gonal-f®, Long GnRH agonist, GnRH antagonist
- Where
- Germany
- Volunteers
- 1,064 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Fertility, Male Fertility
Sperm, Exposure and Endocrine Disruptors
The proposed research aims to 1) measure male participants' urinary levels of EDCs and sperm quality before and after report-back and EDC reduction intervention and assess changes, 2) assess the extent to which MM's program…
- Conditions
- Fertility, Male Fertility, Sperm Count, Low, Sperm Quality
- Trial name
- SEED (NCT07703046)
- Testing
- EDC Education Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Million Marker Wellness, Inc.
Infertility
Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage
The purpose of this study is to demonstrate that the Eeva System may be used to identify embryos on Day 2 that are most likely to form blastocysts.
- Trial name
- Eeva (NCT01369446)
- Testing
- Eeva System Study
- Where
- 5 sites in United States
- Volunteers
- 160 people
- Sponsor
- Progyny, Inc.
Infertility
Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1
This trial investigates the effects of FE 999049 compared to GONAL-F.
- Trial name
- ESTHER-1 (NCT01956110)
- Testing
- Follitropin Delta (FE 999049), Follitropin Alfa (GONAL-F)
- Where
- 13 sites in Belgium, Brazil and 9 more
- Volunteers
- 1,329 people
- Sponsor
- Ferring Pharmaceuticals
Hypohidrotic Ectodermal Dysplasia, X-Linked Hypohidrotic Ectodermal Dysplasia
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey
In this survey of X-Lined Hypohidrotic Ectodermal Dysplasia (XLHED) carrier females, Edimer proposes to review responses to an XLHED Carrier Outlook toward Reproduction Survey in order to understand attitudes toward reproduction…
- Trial name
- X-CORS (NCT01398813)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Edimer Pharmaceuticals
Infertility
Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Techniques in Spain.
Non-comparative, observational, ambispective post-authorisation study (EPA-SP).
- Trial name
- BIRTH (NCT02941341)
- Testing
- r-hFSH
- Where
- Spain
- Volunteers
- 1,222 people
- Sponsor
- Finox AG
Diet; Deficiency
Cross-sectional Dietary Intake Survey on Ivorian School-Aged Children and Women of Reproductive Age
A cross-sectional dietary intake study was conducted with 423 Ivorian school aged children (SAC, 6-12 years) and 423 women of reproductive age (WRA, 15-49 years) from four cities, recruited by two-stage random sampling.
- Trial name
- AN (NCT06175130)
- Where
- Netherlands
- Volunteers
- 846 people, healthy volunteers welcome
- Sponsor
- FrieslandCampina
Infertility
Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle
This is a multicenter, prospective randomized controlled, interventional investigation to assess the safety and clinical performance of Forielle, a medical device for endometrial washing, in restoring favorable endometrial…
- Trial name
- ENDOMEDE (NCT03387059)
- Testing
- Forielle
- Where
- 7 sites in Italy
- Volunteers
- 9 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Endometriosis, Reproductive System Disorder
Developing an US-MRI Biomarker Fusion Model for Endometriosis
Single centre, prospective, observational, cohort study looking to develop a database representing the variability of disease and imaging seen in women with clinically diagnosed endometriosis, awaiting laparoscopic surgery.
- Trial name
- DEFEND (NCT04974710)
- Testing
- Outpatient MRI
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Perspectum
Infertility of Uterine Origin
Development of a Microbiome Non-invasive Diagnosis Tool
Although the endometrium tissue has been traditionally considered free of bacteria, recent studies have documented the presence of an endometrial microbiome.
- Trial name
- ERA-niMIC (NCT03330444)
- Testing
- Endometrial biopsy and endometrial fluid collection
- Where
- 13 sites in United States, Argentina and 6 more
- Volunteers
- 452 people, healthy volunteers welcome
- Sponsor
- Igenomix
Infertility
A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment
This is a multicenter retrospective study in good prognosis Chinese patients. Data will be collected from infertile women who underwent first in vitro fertilization (IVF)/intra cytoplasmic sperm injection (ICSI) using a…
- Trial name
- FASSION (NCT02889380)
- Testing
- No Intervention
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Infertility, Ovarian Stimulation
A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
In-vitro fertilization (IVF) of human oocytes followed by the replacement of embryo in the uterine cavity has become a well established treatment for female infertility attributable to damaged fallopian tubes, endometriosis or…
- Trial name
- NCT01121991
- Testing
- Recombinant Human-Luteinizing Hormone (Luveris)
- Volunteers
- 55 people
- Sponsor
- EMD Serono
Infertility, Ovulation Induction
A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age
Ovarian reserve is related to chronological age; 35 years of age is the accepted threshold for significant decline in assisted reproductive technologies (ART) success with scarce follicular recruitment and poor oocyte retrieval.
- Trial name
- NCT01079949
- Testing
- r-hLH + r-hFSH, r-hFSH, Recombinant Human Choriogonadotropin (r-hCG)
- Where
- Spain
- Volunteers
- 93 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Infertility, Ovulation Induction
A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age
This is a multicentric, open, randomized, comparative trial aimed to assess the influence of recombinant luteinizing hormone (r-LH) supplementation during controlled ovarian stimulation (COS) in advanced reproductive age in terms…
- Trial name
- NCT01075815
- Testing
- Recombinant human luteinizing hormone (rhLH), Recombinant follicle-stimulating hormone (rFSH)
- Where
- Spain
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Infertile Women Undergoing Assisted Reproductive Technology (ART)
A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation
To demonstrate the comparative safety and efficacy of Cetrotide® 3 milligram (mg) and Antagon™ in the inhibition of a premature luteinizing hormone (LH) surge in women undergoing ovarian stimulation with recombinant human…
- Trial name
- NCT00298025
- Testing
- Cetrotide®, Antagon ™, Recombinant human follicle stimulating hormone (r-hFSH)
- Volunteers
- 185 people
- Sponsor
- EMD Serono
Dysmenorrhea, Dyspareunia
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in…
- Conditions
- Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
- Trial name
- NCT00318500
- Testing
- ERB-041
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Endometritis
Diagnosis of Chronic Endometritis in Endometrial Fluid Using Molecular Techniques to Improve the Outcomes of Assisted Reproductive Treatments
Chronic endometritis (CE) is a persistent inflammation of the endometrial lining caused by the infection of the uterine cavity mainly by bacterial pathogens.
- Trial name
- ChEndometritis (NCT03169621)
- Testing
- Endometrial Biopsy and endometrial fluid collection
- Where
- Spain
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Igenomix
Infertility
Gene Expression in Cumulus Cells to Predict Pregnancy
The purpose of this study is to determine the performance of a genetic assay, GemART, in cumulus cells predictive of embryo viability, and pregnancy success in women undergoing in vitro fertilization (IVF).
- Trial name
- NCT01732900
- Testing
- Morphology, GemART assay
- Where
- 4 sites in United States
- Volunteers
- 133 people
- Sponsor
- Gema Diagnostics
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals